Rapid and Deep Prostate‐Specific Antigen Decline is a Prognostic Marker in Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Multi‐Intuitional Analysis
Our findings suggested that PSA decline to ≤ 0.2 ng/mL by 12 weeks of treatment may be a useful prognostic biomarker for mHSPC in the real-world setting. The prognostic value of this should be further investigated in a prospective cohort, and identification of an optimal cutoff value is necessary for its application in clinical trial design or clinical practice.
Authors
- Kiyoshi Takahara (ORCID: https://orcid.org/0000-0002-4766-2074)
- Taku Naiki (ORCID: https://orcid.org/0000-0002-7638-6048)
- Takuto Hara (ORCID: https://orcid.org/0000-0003-4524-2815)
- Keita Nakane (ORCID: https://orcid.org/0000-0002-2589-1722)
- Takuya Koie (ORCID: https://orcid.org/0000-0002-2980-127X)
- Takahiro Yasui (ORCID: https://orcid.org/0000-0003-2197-2477)
- Ryoichi Shiroki (ORCID: https://orcid.org/0000-0002-4698-5947)
- Kotaro Suzuki (ORCID: https://orcid.org/0000-0003-4589-9251)
- Hiromitsu Watanabe (ORCID: https://orcid.org/0000-0001-5186-7139)
- Hideaki Miyake
Institutions
- Fujita Health University (JP)
- Hamamatsu University School of Medicine (JP)
- Nagoya City University (JP)
- Gifu University (JP)
- Kobe University (JP)
Publication Details
- Journal
- The Prostate
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1002/pros.24847
- Citations
- 4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.68